Referencia número: HY-101071A

Copy Link Print Information

Monastrol

(Synonyms: (±)-Monastrol)

11 Cited Publications

Revisión del cliente

Based on 11 publication(s) in Google Scholar

Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC₅₀ value of 14 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.89%
No. CAS: 329689-23-8
Fòrmula: C₁₄H₁₆N₂O₃S
Peso molecular:292.35

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Monastrol Chemical Structure

No. CAS: 329689-23-8

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (11)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC₅₀ value of 14 μM.

IC₅₀ & Target^[3]

Eg5

14 μM (IC₅₀)

Ver todos los productos específicos de isoformas Kinesin :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human 786-0 cells Growth inhibition of human 786-0 cells	[PMID: 21855351]
A-431	IC₅₀	53 μg/mL Compound: Monastrol	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	[PMID: 21620531]
A549	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	[PMID: 21855351]
A549	IC₅₀	>10 μM Compound: Monastrol	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 21856161]
A549	IC₅₀	>100 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
A549	IC₅₀	118 μg/mL Compound: Monastrol	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21620531]
ACHN	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human ACHN cells Growth inhibition of human ACHN cells	[PMID: 21855351]
AGS	IC₅₀	>10 μM Compound: Monastrol	Cytotoxicity against human AGS cells after 48 hrs by SRB assay Cytotoxicity against human AGS cells after 48 hrs by SRB assay	[PMID: 21856161]
BXPC-3	EC₅₀	>100 nM Compound: rac-monastrol	Antiproliferative activity against human BxPC3 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BxPC3 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
C6	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against rat C6 cells after 24 hrs by MTS assay Antiproliferative activity against rat C6 cells after 24 hrs by MTS assay	[PMID: 30108989]
C6	IC₅₀	87.83 μM Compound: Manastrol	Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30151081]
CAKI-1	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human Caki1 cells Growth inhibition of human Caki1 cells	[PMID: 21855351]
CCRF-CEM	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human CCRF-CEM cells Growth inhibition of human CCRF-CEM cells	[PMID: 21855351]
COLO 205	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human COLO205 cells Growth inhibition of human COLO205 cells	[PMID: 21855351]
COLO 205	IC₅₀	164 μg/mL Compound: Monastrol	Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 21620531]
EKVX	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human EKVX cells Growth inhibition of human EKVX cells	[PMID: 21855351]
HCC 2998	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human HCC2998 cells Growth inhibition of human HCC2998 cells	[PMID: 21855351]
HCT-116	EC₅₀	1.2 μM Compound: monastrol	Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy	[PMID: 18793847]
HCT-116	EC₅₀	1.5 μM Compound: monastrol	Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy	[PMID: 18793847]
HCT-116	EC₅₀	24155 nM Compound: rac-monastrol	Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
HCT-116	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human HCT116 cells Growth inhibition of human HCT116 cells	[PMID: 21855351]
HCT-116	IC₅₀	>50 μM Compound: Monastrol	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20934346]
HCT-116	IC₅₀	9 μM Compound: 1	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
HCT-15	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human HCT15 cells Growth inhibition of human HCT15 cells	[PMID: 21855351]
HeLa	IC₅₀	176.9 μM Compound: Monastrol	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29908443]
HeLa	IC₅₀	51.3 μM Compound: 1, monastrol	Induction of monoastral spindles in HeLa cells after 7 hrs Induction of monoastral spindles in HeLa cells after 7 hrs	[PMID: 17587586]
HeLa	IC₅₀	6.1 μM Compound: 1, monastrol	Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs	[PMID: 17587586]
HL-60(TB)	GI₅₀	25.1 μM Compound: NSC-716782	Growth inhibition of human HL-60(TB) cells Growth inhibition of human HL-60(TB) cells	[PMID: 21855351]
HL-60(TB)	IC₅₀	0.147 μM Compound: Monastrol	Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay	[PMID: 28667871]
HOP-62	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human HOP62 cells Growth inhibition of human HOP62 cells	[PMID: 21855351]
HT-29	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human HT-29 cells Growth inhibition of human HT-29 cells	[PMID: 21855351]
IGROV-1	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human IGROV1 cells Growth inhibition of human IGROV1 cells	[PMID: 21855351]
K562	EC₅₀	>100 nM Compound: rac-monastrol	Antiproliferative activity against human K562 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human K562 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
K562	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human K562 cells Growth inhibition of human K562 cells	[PMID: 21855351]
KB 3-1	EC₅₀	56494 nM Compound: rac-monastrol	Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay in presence of zosuquidar Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay in presence of zosuquidar	[PMID: 20597485]
KB 3-1	EC₅₀	85114 nM Compound: rac-monastrol	Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
KB-V1	EC₅₀	45394 nM Compound: rac-monastrol	Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar	[PMID: 20597485]
KB-V1	EC₅₀	99083 nM Compound: rac-monastrol	Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay	[PMID: 20597485]
KM12	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human KM12 cells Growth inhibition of human KM12 cells	[PMID: 21855351]
LOX IMVI	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human LOXIMVI cells Growth inhibition of human LOXIMVI cells	[PMID: 21855351]
M14	GI₅₀	25.1 μM Compound: NSC-716782	Growth inhibition of human M14 cells Growth inhibition of human M14 cells	[PMID: 21855351]
Malme-3M	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human MALME-3M cells Growth inhibition of human MALME-3M cells	[PMID: 21855351]
MCF7	IC₅₀	45 μg/mL Compound: Monastrol	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21620531]
MCF7	IC₅₀	59.1 μM Compound: Monastrol	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29908443]
MCF7	IC₅₀	73 μM Compound: 1	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
MM1.S	IC₅₀	8.7 μM Compound: 1	Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
MOLT-4	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human MOLT4 cells Growth inhibition of human MOLT4 cells	[PMID: 21855351]
MOLT-4	IC₅₀	0.215 μM Compound: Monastrol	Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay	[PMID: 28667871]
NCI-H1299	EC₅₀	>100 nM Compound: rac-monastrol	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by Alamar blue assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by Alamar blue assay	[PMID: 20597485]
NCI-H226	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human NCI-H226 cells Growth inhibition of human NCI-H226 cells	[PMID: 21855351]
NCI-H23	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human NCI-H23 cells Growth inhibition of human NCI-H23 cells	[PMID: 21855351]
NCI-H322M	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human NCI-H322M cells Growth inhibition of human NCI-H322M cells	[PMID: 21855351]
NCI-H522	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human NCI-H522 cells Growth inhibition of human NCI-H522 cells	[PMID: 21855351]
OVCAR-3	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR3 cells Growth inhibition of human OVCAR3 cells	[PMID: 21855351]
OVCAR-4	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR4 cells Growth inhibition of human OVCAR4 cells	[PMID: 21855351]
OVCAR-5	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human OVCAR5 cells Growth inhibition of human OVCAR5 cells	[PMID: 21855351]
OVCAR-8	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human OVCAR8 cells Growth inhibition of human OVCAR8 cells	[PMID: 21855351]
SF-268	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human SF268 cells Growth inhibition of human SF268 cells	[PMID: 21855351]
SF-295	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SF295 cells Growth inhibition of human SF295 cells	[PMID: 21855351]
SF-539	GI₅₀	50.1 μM Compound: NSC-716782	Growth inhibition of human SF539 cells Growth inhibition of human SF539 cells	[PMID: 21855351]
SK-MEL-2	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-2 cells Growth inhibition of human SK-MEL-2 cells	[PMID: 21855351]
SK-MEL-28	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-28 cells Growth inhibition of human SK-MEL-28 cells	[PMID: 21855351]
SK-MEL-5	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SK-MEL-5 cells Growth inhibition of human SK-MEL-5 cells	[PMID: 21855351]
SK-OV-3	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human SKOV3 cells Growth inhibition of human SKOV3 cells	[PMID: 21855351]
SN12C	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SN12C cells Growth inhibition of human SN12C cells	[PMID: 21855351]
SNB-19	GI₅₀	79.4 μM Compound: NSC-716782	Growth inhibition of human SNB19 cells Growth inhibition of human SNB19 cells	[PMID: 21855351]
SNB-75	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SNB75 cells Growth inhibition of human SNB75 cells	[PMID: 21855351]
SR	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human SR cells Growth inhibition of human SR cells	[PMID: 21855351]
SW-620	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human SW620 cells Growth inhibition of human SW620 cells	[PMID: 21855351]
TK-10	GI₅₀	100 μM Compound: NSC-716782	Growth inhibition of human TK10 cells Growth inhibition of human TK10 cells	[PMID: 21855351]
U138-MG	IC₅₀	>200 μM Compound: 1	Antiproliferative activity against human U138MG cells after 24 hrs by MTS assay Antiproliferative activity against human U138MG cells after 24 hrs by MTS assay	[PMID: 30108989]
U-251	GI₅₀	31.6 μM Compound: NSC-716782	Growth inhibition of human U251 cells Growth inhibition of human U251 cells	[PMID: 21855351]
UACC-257	GI₅₀	63.1 μM Compound: NSC-716782	Growth inhibition of human UACC257 cells Growth inhibition of human UACC257 cells	[PMID: 21855351]
UACC-62	GI₅₀	39.8 μM Compound: NSC-716782	Growth inhibition of human UACC62 cells Growth inhibition of human UACC62 cells	[PMID: 21855351]
UO-31	GI₅₀	100 μM Compound: NSC-716782	Growth inhibition of human UO31 cells Growth inhibition of human UO31 cells	[PMID: 21855351]

In Vitro

Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. Monastrol treatment of dividing cells results in spindle collapse and cell cycle arrest with a monoastral spindle, which is similar to the phenotype observed when Eg5 is inhibited by anti-Eg5 antibodies^[1]. Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. Monastrol treatment can decrease cell viability in MCF-7 tumor cells. Real-time cell growth kinetic analysis showed a decrease in the proliferation of MCF-7 cells exposed to monastrol^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 329689-23-8
Appearance Solid
Peso molecular 292.35
Fòrmula C₁₄H₁₆N₂O₃S
Color White to off-white
SMILES

O=C(C1=C(C)NC(NC1C2=CC=CC(O)=C2)=S)OCC
Synonyms

(±)-Monastrol
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (11)

All Cell Imaging/StainingCell Proliferation/Viability AssayBio/Physico-chemical AssayFlow Cytometry

Sort by:

Journal Impact Factor

Nat Commun

Epigenetic compartmentalization of mitotic chromosomes by phase-separation-driven repulsion between WDR5 and the chromosomal passenger complex. [Abstract]

2026 Jun 16. PMID: 42303627
Nat Commun

Polar chromosomes are rescued from missegregation by spindle elongation-driven microtubule pivoting. [Abstract]

2026 Mar 17;17(1):2049. PMID: 41844586

Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049. [Abstract]

Time-lapse images of RPE1 cells stably expressing CENP-A-GFP and Centrin1-GFP (colorful, confocal) for Monastrol (100 μM)-treated cells.

Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049. [Abstract]

The washout of the Eg5 inhibitor Monastrol reversed the inhibitor-induced spindle shortening into elongation, which triggered kinetochore pivoting towards the main spindle surface.

Monastrol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2026 Mar 17;17(1):2049. [Abstract]

The experimental correlation of the pivoting angle change and spindle length change for the control (orange), DMSO control (dark green), Monastrol washout (light green), FCPT (blue), Monastrol (purple) and STLC (yellow) treatments along with the theoretical curve calculated based on the experimental parameters from DMSO and STLC experiments.
Int J Biol Sci

KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer. [Abstract]

2021 Jan 1;17(2):514-526. PMID: 33613109

Monastrol purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Jan 1;17(2):514-526. [Abstract]

The cell growth curve of NOZ and EH-GB1 exposed to different concentration Monastrol (0, 5, 10, 15, 20 μM) for different lengths of time (0h, 24h, 48h, 72h).

Monastrol purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Jan 1;17(2):514-526. [Abstract]

Cell cycle distribution after 48 hours of Monastrol treatment (15μM and 20 μM).
Proc Natl Acad Sci U S A

The RPA-RNF20-SNF2H cascade promotes proper chromosome segregation and homologous recombination repair. [Abstract]

2023 May 16;120(20):e2303479120. PMID: 37155876
Hum Reprod

Pathogenic variants in DLGAP5 cause female infertility characterized by oocyte maturation arrest and embryonic arrest. [Abstract]

2025 Sep 1;40(9):1773-1785. PMID: 40639803
J Cell Biol

High-content phenotyping reveals Golgi dynamics and their role in cell cycle regulation. [Abstract]

2026 Jan 5;225(1):e202503083. PMID: 41236476
Comput Struct Biotechnol J

Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. [Abstract]

2021 Oct 1:19:5568-5577. PMID: 34712400
Gene

Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles. [Abstract]

2025 Jul 5:955:149458. PMID: 40187619
bioRxiv

2025 March 06.
bioRxiv

2024 October 01.
bioRxiv

2024 June 16.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (342.06 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4206 mL

17.1028 mL

34.2056 mL

5 mM

0.6841 mL

3.4206 mL

6.8411 mL

10 mM

0.3421 mL

1.7103 mL

3.4206 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[2]

The cytotoxicity assay is performed with MTT. Cells are seeded in 96-well culture plates (5000 cells/well) and incubated for 24 h for stabilization. After this period, the following treatments are administered for 24 and 48 h: vehicle control (0.5 % DMSO); 1 μM doxorubicin and monastrol at 5, 25, 50, 75, and 100 μM. After each time of treatment, the medium is withdrawn, serum-free media containing 0.5 mg/mL MTT salt is added and incubated for 4 h, and formazan crystal products are diluted^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Cochran JC, et al. Monastrol inhibition of the mitotic kinesin Eg5. J BiolChem. 2005 Apr 1;280(13):12658-67. [Content Brief]

[2]. Mayer TU, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999 Oct 29;286(5441):971-4. [Content Brief]

[3]. Marques LA, et al. Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells. Naunyn Schmiedebergs Arch Pharmacol. 2016 Dec;389(12):1279-1288. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4206 mL	17.1028 mL	34.2056 mL	85.5139 mL
	5 mM	0.6841 mL	3.4206 mL	6.8411 mL	17.1028 mL
	10 mM	0.3421 mL	1.7103 mL	3.4206 mL	8.5514 mL
	15 mM	0.2280 mL	1.1402 mL	2.2804 mL	5.7009 mL
	20 mM	0.1710 mL	0.8551 mL	1.7103 mL	4.2757 mL
	25 mM	0.1368 mL	0.6841 mL	1.3682 mL	3.4206 mL
	30 mM	0.1140 mL	0.5701 mL	1.1402 mL	2.8505 mL
	40 mM	0.0855 mL	0.4276 mL	0.8551 mL	2.1378 mL
	50 mM	0.0684 mL	0.3421 mL	0.6841 mL	1.7103 mL
	60 mM	0.0570 mL	0.2850 mL	0.5701 mL	1.4252 mL
	80 mM	0.0428 mL	0.2138 mL	0.4276 mL	1.0689 mL
	100 mM	0.0342 mL	0.1710 mL	0.3421 mL	0.8551 mL

Keywords

Monastrol

11 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Monastrol

Anti-Cancer Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Targeted Diversity Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

3D Diverse Fragment Library

Anti-Aging Compound Library Mini

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Publications Citing Use of MedChemExpress (MCE) Monastrol

Ver todos los productos específicos de isoformas Kinesin

Actividad biológica

Chemical Information

Publications (11)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Monastrol

Anti-Cancer Compound Library

Anti-Aging Compound Library

Cytoskeleton Compound Library

Targeted Diversity Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

3D Diverse Fragment Library

Anti-Aging Compound Library Mini

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Publications Citing Use of MedChemExpress (MCE) Monastrol

Ver todos los productos específicos de isoformas Kinesin

Actividad biológica

Chemical Information

Publications (11)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Monastrol Related Classifications

HY-101071A Related Classifications